Results 51 to 60 of about 77,485 (311)

Botulinum and Tetanus Neurotoxins

Annual Review of Biochemistry, 2019
Botulinum neurotoxins (BoNTs) and tetanus neurotoxin (TeNT) are the most potent toxins known and cause botulism and tetanus, respectively. BoNTs are also widely utilized as therapeutic toxins. They contain three functional domains responsible for receptor-binding, membrane translocation, and proteolytic cleavage of host proteins required for synaptic ...
Min, Dong, Geoffrey, Masuyer, Pål, Stenmark   +2 more
openaire   +3 more sources

Emergency response to a cluster of suspected food-borne botulism in Abuja, Nigeria: challenges with diagnosis and treatment in a resource-poor setting

The Pan African Medical Journal, 2020
Food-borne botulism is a rare, acute and potentially fatal neurologic disorder that results from ingestion of food contaminated by botulinum toxin released from the anaerobic, spore-forming, gram-positive bacterium Clostridium botulinum.
Oyeladun Okunromade, Mahmood Muazu Dalhat, Aminatu Makarfi Umar, Augustine Olajide Dada, Jamilu Nikau, Lamin Maneh, Okokon Ita Ita, Muhammad Shakir Balogun, Patrick Nguku, Olubunmi Ojo, Chikwe Ihekweazu   +10 more
doaj   +1 more source

A Targeted Therapeutic Rescues Botulinum Toxin-A Poisoned Neurons [PDF]

, 2008
Botulinum neurotoxin (BoNT), a Category A biothreat agent, is the most potent poison known to mankind. Currently no antidote is available to rescue poisoned synapses.
Radharaman Ray, James Keller, Bal Ram Singh, Prabhati Ray, Peng Zhang, Michael Adler, Dan Li   +6 more
core  

Tumour‐proximal deep serum proteomics identifies biomarkers associated with ovarian cancer

Molecular Oncology, EarlyView.
New biomarkers are needed for early ovarian cancer detection. Ovarian (tumour‐proximal) and peripheral vein serum from healthy women and patients with benign or malignant tumours underwent nanoparticle‐enriched deep proteomics. Ovarian serum yielded more protein identifications and revealed tumour‐reflective signatures.
Darren Lau, Daniel Pincher, Clifford Young, Nicholas Chappell, Noor A. Lokman, Parul Mittal, Leigh Donnellan, Martin K. Oehler, Doug A. Brooks, Peter Hoffmann   +9 more
wiley   +1 more source

The clinical features, diagnosis, and treatment of cognitive impairments in Parkinson's disease

Неврология, нейропсихиатрия, психосоматика, 2017
The review presents the data of recent studies dealing with cognitive impairments (CI) in patients with Parkinson's disease (PD) and gives their characteristics and epidemiology, the specific features of the pathogenesis and clinical manifestations, as ...
G. N. Akhmadeeva, R. V. Magzhanov, G. N. Tayupova, A. R. Baitimerov   +3 more
doaj   +1 more source

Botulinum in selected neurological disorders - review

Journal of Pre-Clinical and Clinical Research, 2021
Introduction and objective Botulinum toxin (BoNT) has been used in medicine for many years. BoNT, prevents acetylcholine from being released into synapses, causing flaccid muscles paralysis.
Agata Rocka, Faustyna Piędel, Patryk Piotr Jasielski, Mikołaj Piwek, Véronique Petit, Konrad Rejdak   +5 more
doaj   +1 more source

Generalized Dystonia With Cervical Predominance in a Patient With a De Novo TCF20 Variant

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT TCF20 has been implicated in developmental delay and intellectual disability, with dystonia reported less frequently. We describe a woman in her early twenties with childhood‐onset learning difficulties, progressive dysarthria, tremor, and generalized dystonia with marked cervical predominance, associated with a de novo TCF20 frameshift ...
Melisa Kilic, Petr Dusek, Ibrahim Kamaci, Bahar Gulmez, Gul Yalcin Cakmakli, Ersin Tan, Sibel Ugur Iseri, Zuhal Yapici   +7 more
wiley   +1 more source

Facial Cosmetic Therapy Use Among Patients With Systemic Sclerosis: An Australian Cohort Study

Arthritis Care &Research, EarlyView.
Objective Systemic sclerosis (SSc) is associated with numerous facial manifestations for which patients may engage in cosmetic therapies. It is unclear how patients with SSc use these therapies. This study sought to characterize patient engagement and experiences with cosmetic therapies for SSc‐related and non‐SSc–related facial changes.
Zachary Warren, Diane Apostolopoulos, Gene‐Siew Ngian, Amanda M. Saracino, Laura Ross, Nava Ferdowsi, Jennifer Walker, Cindy Hall, Kim Griggs, Susanna Proudman, Wendy Stevens, Joanne Sahhar   +11 more
wiley   +1 more source

A Novel Surface Plasmon Resonance Biosensor for the Rapid Detection of Botulinum Neurotoxins

Biosensors, 2017
Botulinum neurotoxins (BoNTs) are Category A agents on the NIAID (National Institute of Allergy and Infectious Diseases) priority pathogen list owing to their extreme toxicity and the relative ease of production. These deadly toxins, in minute quantities
Kruti Patel, Shmuel Halevi, Paul Melman, John Schwartz, Shuowei Cai, Bal Ram Singh   +5 more
doaj   +1 more source

Endogenous CRISPR-Cas Systems in Group I Clostridium botulinum and Clostridium sporogenes Do Not Directly Target the Botulinum Neurotoxin Gene Cluster

Frontiers in Microbiology, 2022
Most strains of proteolytic group I Clostridium botulinum (G1 C. botulinum) and some strains of Clostridium sporogenes possess genes encoding botulinum neurotoxin (BoNT), a potent neuroparalytic agent. Within G1 C. botulinum, conserved bont gene clusters
Travis G. Wentz, Travis G. Wentz, Travis G. Wentz, Benjamin J. M. Tremblay, Marite Bradshaw, Andrew C. Doxey, Shashi K. Sharma, John-Demian Sauer, Sabine Pellett   +8 more
doaj   +1 more source